In this manuscript, we present the development, characterization, and optimization of a first-in-class CAR-T cell therapy targeting CD74, an invariant chain of MHC class II HLA-DR, which is overexpressed on MCL cells. The gene discussed is CD74; the disease is mantle cell lymphoma.